(1 - 16 von 24
)
Investegate |Amryt Pharma PLC Announcements | Amryt Pharma PLC:...
www.investegate.co.uk
Investegate announcements from Amryt Pharma PLC, POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
Amryt Pharma PLC: Amryt to present updates InvestEgatewww.investegate.co.uk › rns › amr...
www.investegate.co.uk
Amryt's Chief Medical Officer - Dr Mark Sumeray - will present on the Amryt research programme as part of the conference programme on ...
Career and Jobs News - Essentials
essentials.news
... today announced that the company has added highly experienced biotech executive Mark Sumeray, M.D., MS, FRCS, as chief medical officer. › biotech › career › article › amolyt...
AMYT Share News - London South East
www.lse.co.uk
... discussions with the respective health authorities to progress lomitapide as a potential treatment for FCS," said chief medical officer Dr Mark Sumeray. › news › AM...
French Biotech Database - Biotechgate
www.biotechgate.com
Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer · Read more ››. By: GlobenewsWire Jun › news
Amryt Pharma 'delighted' to kick off Episalvan trial
www.centralcharts.com
Mark Sumeray, chief medical officer for Amryt Pharma PLC (LON:AMYT) tells Proactive's Andrew Scott they're delighted to have enrolled their ...
Aegerion begins Phase III study of lomitapide in Japan to treat HoFH...
www.clinicaltrialsarena.com
Aegerion chief medical officer Mark Sumeray said the pivotal trial marks an important milestone for the company and Japanese HoFH patients.
AZP-3601's Efficacy Data Support Phase 3 Trial Next Year ...
hypoparathyroidismnews.com
— ... safety and efficacy data from Cohort [group] 2 validate the findings from the first cohort of patients in this study,” Mark Sumeray, MD, ... › ...
Amolyt Pharma publishes hypoparathyroidism treatment results
www.labiotech.eu
— validate the findings from the first cohort of patients in this study,” said Mark Sumeray, chief medical officer at Amolyt Pharma. › amolyt-...
Amolyt Pharma to Present Full Phase 2a Data on FOX40
fox40.com
— At the International HypoPARAthyroidism Conference, Amolyt Pharma's Chief Medical Officer Mark Sumeray, M.D., will discuss the ... › globenewswire
Positive EB Trial Data Puts Filsuvez on Track for Regulatory ...
epidermolysisbullosanews.com
— ... pediatric disease has been a challenging but enormously important undertaking,” said Mark Sumeray, MD, chief medical officer of Amryt. › ...
POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
www.globenewswire.com
Dr Mark Sumeray, Chief Medical Officer of Amryt commented: “The ... on the speed of wound healing in such a complex clinical situation.
sortiert nach Relevanz / Datum